Mark Andrew Wilson sold $45k of NKTR
Chief Legal Officer at NEKTAR THERAPEUTICS. 49,962 shares at an average of $0.90, traded Dec 23, 2024, filed Dec 26, 2024.
Score components
- +15RoleOfficer
- +6Trade size$45k at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-140591, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | SOpen-market sale Common Stock | -33,402 | $0.90 | $30k | 351,892 | Dec 26, 2024 |
| Dec 24, 2024 | SOpen-market sale Common Stock | -16,560 | $0.89 | $15k | 335,332 | Dec 26, 2024 |
Related signals
Other insiders at NEKTAR THERAPEUTICS and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $31k 423 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 180 shares | -1% | |
| 11Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $138k 3,867 shares | -15% | |
| 50Moderate | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $120k 2,207 shares | -4% | |
| 36Weak | NEKTAR THERAPEUTICS | Mark Andrew Wilson Chief Legal Officer | $34k 630 shares | -3% | |
| 38Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $63k 1,157 shares | -6% | |
| 32Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $311k 6,666 shares | -12% | |
| 35Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $431k 11,832 shares | -17% | |
| 10Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $58k 1,721 shares | -9% | |
| 26Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $45k 1,500 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.